The effect of raloxifene on symptoms and cognitive functioning in a postmenopausal schizophrenia patient: a case report

Archives of Women's Mental Health

Volumn 18, Issue 2, 2015, Pages 259-261

  Huerta Ramos, Elena ^a,b,c   Ochoa, Susana ^a,c   Roca, Mercedes ^a,c   Miquel, Eva ^a   Usall, Judith ^a,c  

^a PARC SANITARI SANT JOAN DE DÉU   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

Cognitive function; Postmenopausal women; Psychopathology; Raloxifene; Schizophrenia

Indexed keywords

BIPERIDEN; CLOZAPINE; DEXAMETHASONE; GLIBENCLAMIDE; HALOPERIDOL; METFORMIN; PLACEBO; RALOXIFENE; SIMVASTATIN; SOLIFENACIN; TOLTERODINE; NEUROLEPTIC AGENT; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADJUVANT THERAPY; ADULT; ARTICLE; CASE REPORT; CAUCASIAN; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DSM-IV-TR; EXECUTIVE FUNCTION; FEMALE; HUMAN; LONG TERM MEMORY; MEDICAL HISTORY; MENTAL HOSPITAL; MENTAL PATIENT; MIDDLE AGED; NEUROPSYCHOLOGICAL TEST; POSITIVE AND NEGATIVE SYNDROME SCALE; POSTMENOPAUSE; PRIORITY JOURNAL; SCHIZOPHRENIA; STROOP TEST; TREATMENT DURATION; WECHSLER INTELLIGENCE SCALE; COGNITION; COGNITION DISORDERS; DRUG COMBINATION; DRUG EFFECTS; PSYCHOLOGICAL RATING SCALE; PSYCHOLOGY; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; COGNITION; COGNITION DISORDERS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PSYCHIATRIC STATUS RATING SCALES; RALOXIFENE; SCHIZOPHRENIA; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME;

EID: 84925489700     PISSN: 14341816     EISSN: 14351102     Source Type: Journal    
DOI: 10.1007/s00737-015-0500-9     Document Type: Article

References (16)

1. Benedet MJ, Alexandre MA (1998) Test de aprendizaje verbal España-Complutense (TAVEC). TEA, Madrid
2. Huerta-Ramos E, Iniesta R, Ochoa S, Cobo J, Miquel E, Roca M, Serrano-Blanco A, Teba F, Usall J (2014) Effects of raloxifene on cognition in postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. Eur Neuropsychopharmacol 24:223–231
3. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261–276
4. Kianimehr G, Fatehi F, Hashempoor S, Khodaei-Ardakani MR, Rezaei F, Nazari A, Kashani L, Akhondzadeh S (2014) Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo-controlled trial. Daru 22:55
5. Ko SS, Jordan VC (2011) Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene. Expert Opin Pharmacother 12:657–674
6. Kulkarni J, Gurvich C, Lee SJ, Gilbert H, Gavrilidis E, de Castella A, Berk M, Dodd S, Fitzgerald PB, Davis SR (2010) Piloting the effective therapeutic dose of adjunctive selective estrogen receptor modulator treatment in postmenopausal women with schizophrenia. Psychoneuroendocrinology 35:1142–1147
7. Landry M, Di Paolo T (2003) Effect of chronic estradiol, tamoxifen or raloxifene treatment on serotonin 5-HT1A receptor. Brain Res Mol Brain Res 112:82–89
8. Landry M, Lévesque D, Di Paolo T (2002) Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain. Neuroendocrinology 76:214–222
9. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and across-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 334:1–100
10. Reitan R, Wolfson D (1995) Category test and trail making test as measures of frontal lobe functions. Clin Neuropsychol 9:50–56
11. Seisdedos N, Corral S, Cordero A, de la Cruz MV, Hernández MV, Pereña J (1999) WAIS III. Manual Técnico. TEA, Madrid
12. Strauss E, Sherman EMS, Spreen O (2006) A compendium of neuropsychological tests: administration, norms, and commen- tary, 3rd edn. Oxford University Press, New York
13. Stroop JR (1935) Studies of interference in serial verbal reactions. J Exp Psychol 18:643–662
14. Usall J, Huerta-Ramos E, Iniesta R, Cobo J, Araya S, Roca M, Serrano-Blanco A, Teba F, Ochoa S (2011) Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 72:1552–1557
15. Wong J, Seeman MV, Shapiro H (2003) Case report: raloxifene in postmenopausal women with psychosis: preliminary findings. Am J Geriatr Psychiatry 11:697–698
16. Zec RF, Trivedi MA (2002) The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review. Neuropsychol Rev 12:65–109